Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ETCompany ParticipantsBryan Giraudo - COO & CFOFaheem Hasnain ...

Skip to main content Search Newsletters Watchlist ...

The 34-year-old Philadelphia Maritime Museum has been transformed into Independence Seaport Museum on the waterfront at Penn’s Landing. The $15-million museum, which opens next Sunday in the ...

Women treated with IMNN-001 and standard of care chemotherapy plus PARP inhibitors achieved nearly 12-month increase in PFS compared to standard of care; median OS in IMNN-001 treatment arm not ...

The presentations will cover various topics related to the company's oral bradykinin B2 receptor antagonist, deucrictibant, highlighting research on its long-term safety, efficacy, and quality of ...

Four oral presentations will feature Ascendis clinical trial results, including 4-year efficacy and safety data from the Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide ...

(MENAFN- GlobeNewsWire - Nasdaq) Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data ...

An oral presentation will feature ALLO-316, an investigational AlloCAR T product targeting CD70. ALLO-316 is currently being studied in patients with advanced or metastatic renal cell carcinoma (RCC).

Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) SAN DIEGO, ...

The data were from the Phase 2 clinical study of high-dose IBI302 (NCT05403749) to evaluate the efficacy, safety and dosing intervals in patients with nAMD over a one-year treatment period. A ...

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with ...